Neuroendocrine tumors are rare, but incidence in the United States has climbed steadily: from 1.09 per 100,000 in 1973 to 6.98 per 100,000 by 2012, with continued increases through 2021. Among adults 65 and older, incidence reached 28.44 per 100,000 — more than a fivefold increase over earlier decades — and roughly 8,000 new gastrointestinal neuroendocrine tumors are diagnosed annually in the U.S.
AAVBC's Carcinoid Tumors Quick Reference Guide equips primary care clinicians and care teams with a comprehensive, evidence-aligned reference covering ICD-10 and HCC/RAF V28 coding specificity, carcinoid syndrome recognition and atypical presentations, geriatric risk factors and key differentials, MEAT documentation standards, therapy escalation criteria, NCCN-aligned treatment by subtype, grade, and patient profile, comorbidity management, and quality metrics. Grounded in current WHO 2019 tumor classification and NCCN v1.2026 guidance, this guide supports consistent, individualized clinical decision-making— helping care teams recognize carcinoid tumors earlier, document clinical complexity completely, and coordinate longitudinal care that improves outcomes while reducing avoidable hospitalizations and readmissions.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of carcinoid tumors — moving far beyond quick-reference essentials. These guides provide an integrated review of epidemiology, diagnostic strategy, staging, coding logic, MEAT-aligned documentation examples, treatment guidelines, review vulnerabilities, and cost-utilization considerations. The Deep-Dive combines evidence-informed clinical guidance with practical operational tools to support a deeper understanding of disease complexity and provide multidisciplinary teams with strategies to thrive within value-based frameworks.
Neuroendocrine tumors are rare, but incidence in the United States has climbed steadily: from 1.09 per 100,000 in 1973 to 6.98 per 100,000 by 2012, with continued increases through 2021. Among adults 65 and older, incidence reached 28.44 per 100,000 — more than a fivefold increase over earlier decades — and roughly 8,000 new gastrointestinal neuroendocrine tumors are diagnosed annually in the U.S.
AAVBC's Carcinoid Tumors Quick Reference Guide equips primary care clinicians and care teams with a comprehensive, evidence-aligned reference covering ICD-10 and HCC/RAF V28 coding specificity, carcinoid syndrome recognition and atypical presentations, geriatric risk factors and key differentials, MEAT documentation standards, therapy escalation criteria, NCCN-aligned treatment by subtype, grade, and patient profile, comorbidity management, and quality metrics. Grounded in current WHO 2019 tumor classification and NCCN v1.2026 guidance, this guide supports consistent, individualized clinical decision-making— helping care teams recognize carcinoid tumors earlier, document clinical complexity completely, and coordinate longitudinal care that improves outcomes while reducing avoidable hospitalizations and readmissions.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of carcinoid tumors — moving far beyond quick-reference essentials. These guides provide an integrated review of epidemiology, diagnostic strategy, staging, coding logic, MEAT-aligned documentation examples, treatment guidelines, review vulnerabilities, and cost-utilization considerations. The Deep-Dive combines evidence-informed clinical guidance with practical operational tools to support a deeper understanding of disease complexity and provide multidisciplinary teams with strategies to thrive within value-based frameworks.
